ALL
Pharma?in?China
Pharma?Experts
Market News
Products Guide
Brand Story
-
Paratek Announces FDA Approval of NUZYRA? for Treatment of Community-Acquired Bacterial Pneumonia americanpharmaceuticalreview
June 04, 2021Paratek Pharmaceuticals Inc. announced that the U.S. FDA has approved the Company’s supplemental New Drug Application (sNDA) for the oral-only dosing regimen of NUZYRA? for the treatment of adults with Community-Acquired Bacterial Pneumonia (CABP). -
Sinovant Sciences and Nabriva Therapeutics Announce Positive Topline Results from Phase 3 Trial of Lefamulin in Chinese Adults with Community Acquired Bacterial Pneumonia (CABP) prnasia
May 26, 2021Sinovant Sciences today announced positive topline results from Sinovant's Phase 3 bridging study of lefamulin in Chinese adults with community acquired bacterial pneumonia (CABP). -
XENLETA Demonstrates High Efficacy in Community-Acquired Bacterial Pneumonia americanpharmaceuticalreview
October 16, 2020Nabriva Therapeutics announced in a post-hoc analysis of the Lefamulin Evaluation Against Pneumonia (LEAP) 1 and LEAP 2 trials by age, XENLETA? (lefamulin) demonstrated consistently high efficacy and similar safety and tolerability profiles across all ... -
EU accepts marketing application for Paratek’s antibiotic
pharmatimes
October 11, 2018European regulators have accepted an application from Paratek Pharmaceuticals seeking approval of the broad-spectrum antibiotic omadacycline for two types of infection.
Pharma Sources Insight January 2025
